The present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment […]
Epstein-Barr virus infection can engender severe B-cell lymphoproliferative disorders in immunocompromised individuals. In immunocompetent […]
Tumour-specific molecular targets and alternative therapeutic strategies for triplenegative breast cancer (TNBC) are urgently needed. The protease […]
The evidences provided by the present patent application demonstrate the therapeutic effect of succinate dehydrogenase inhibition to counteract the […]
The present invention relates to the treatment of cancer and particularly of lung cancer. In the present study, the inventors analyzed the role of the […]
Thanks to its very high genome-editing efficiency, CRISPR-Cas9 technology could be a promising anti-cancer weapon. Clinical trials using CRISPR-Cas9 […]
The present invention relates to the adoptive therapy using notably CAR-T cells. Herethe inventors used a lentiviral vector approach to silence RINF […]
The invention relates to a bispecific antibody targeting TfR1 and a soluble antigen. The inventors demonstrate that the unique mode of interaction of […]
Dose-limiting toxicity poses a major limitation to the clinical utility of targeted cancer therapies, often arising from target engagement in […]
Chemotherapy resistance is the major therapeutic barrier in acute myeloid leukemia (AML). To address this issue, the inventors generated a syngeneic […]